The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients

References

• Rose, N. R., and C. Bona. 1993. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today. 14: 426–430
   PubMedGoogle Scholar
• Weiner, H. L. 2004. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 61: 1613–1615
   PubMed Web of Science ®Google Scholar
• Compston, A., and A. Coles. 2002. Multiple sclerosis. Lancet. 359:1221–1231
   PubMed Web of Science ®Google Scholar
• Frohman, E. M., M. Filippi, O. Stuve, et al. 2005. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62: 1345–1356
   PubMedGoogle Scholar
• McQualter, J. L., and C. C. A. Bernard. 2007. Multiple sclerosis: a battle between destruction and repair. J. Neurochem. 100: 295–306
   PubMed Web of Science ®Google Scholar
• Lassmann, H., W. Brück, and C. Lucchinetti. 2001. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7: 115–121
   PubMed Web of Science ®Google Scholar
• Hamann, I., F. Zipp, and C. Infante-Duarte. 2008. Therapeutic targeting of chemokines signaling in Multiple Sclerosis. J. Neurol. Sci. 274: 31–38
   PubMed Web of Science ®Google Scholar
• Ubogu, E. E., M. B. Cossoy, and R. M. Ransohoff. 2006. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27: 48–55
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara, C., J. Ramos-Cejudo, L. S. Aroeira, et al. 2012. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol. 12: 95 . doi: 10.1186/1471-2377-12-95
   PubMedGoogle Scholar
• Sharief, M. K., and R. Hentges. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325: 467–472
   PubMed Web of Science ®Google Scholar
• Vartanian, T., Y. Li, M. Zhao, and K. Stefansson. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1: 732–743
   PubMed Web of Science ®Google Scholar
• Murphy, K. M., and S. L. Reiner. 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2: 933–944
   PubMed Web of Science ®Google Scholar
• Segal, B. M. 2003. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 3: 86–93
   PubMed Web of Science ®Google Scholar
• Miller, A., L. Glass-Marmor, M. Abraham, et al. 2004. Biomarkers of disease activity and response to therapy in multiple sclerosis. Clin. Neurol. Neurosurg. 106: 249–254
   PubMed Web of Science ®Google Scholar
• Imitola, J., T. Chitnis, and S. J. Khoury. 2005. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 106: 163–177
   PubMed Web of Science ®Google Scholar
• Spuler, S., T. Yousry, A. Scheller, et al. 1996. Multiple sclerosis: prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J. Neuroimmunol. 66: 57–64
   PubMed Web of Science ®Google Scholar
• Frisullo, G., V. Nociti, R. Iorio, et al. 2008. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 44: 22–25
   PubMed Web of Science ®Google Scholar
• Kallaur, A. P., S. R. Oliveira, A. N. Colado Simão, et al. 2013. Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol. Med. Rep. 7: 1010–1020
   PubMed Web of Science ®Google Scholar
• Wen, S. R., G. J. Liu, R. N. Feng, et al. 2012. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 244: 94–96
   PubMed Web of Science ®Google Scholar
• Chen, Y. C., S. D. Chen, L. Miao, et al. 2012. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J. Neuroimmunol. 243: 56–60
   PubMed Web of Science ®Google Scholar
• Tang, C., S. Chen, H. Qian, and W. Huang. 2012. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 135: 112–124
   PubMed Web of Science ®Google Scholar
• Dujmovic, I., K. Mangano, T. Pekmezovic, et al. 2009. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J. Neuroimmunol. 207: 101–106
   PubMed Web of Science ®Google Scholar
• Gruol, D. L., and T. E. Nelson. 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15: 307–339
   PubMed Web of Science ®Google Scholar
• Lund, B. T., N. Ashikian, H. Q. Ta, et al. 2004. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J. Neuroimmunol. 155: 161–171
   PubMed Web of Science ®Google Scholar
• Comabella, M., J. Imitola, H. L. Weiner, and S.J. Khoury. 2002. Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J. Neuroimmunol. 126: 205–212
   PubMed Web of Science ®Google Scholar
• Mellergård, J., M. Edström, M. Vrethem, et al. 2010. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler. 16: 208–217
   PubMed Web of Science ®Google Scholar
• O'Connell, K., J. Thakore, and K. K. Dev. 2013. Levels of S100B are raised in female patients with schizophrenia. BMC Psychiatry. 13: 146 . doi: 10.1186/1471-244X-13-146
   PubMed Web of Science ®Google Scholar
• Rothermundt, M., M. Peters, J. H. Prehn, and V. Arolt. 2003. S100B in brain damage and neurodegeneration. Microsc. Res. Tech. 60: 614–632
   PubMed Web of Science ®Google Scholar
• Sen, J., and A. Belli. 2007. S100B in neuropathologic states: the CRP of the brain? J. Neurosci. Res. 85: 1373–1380
   PubMed Web of Science ®Google Scholar
• O'Connell, K. E., J. Thakore, and K. K. Dev. 2014. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophrenia Res. 156: 1–8
   PubMed Web of Science ®Google Scholar
• Chatterjee, S., J. D. Szustakowski, N. R. Nanguneri, et al. 2009. Identification of novel genes and pathways regulating SREBP transcriptional activity. PLoS One. 4: e5197
   PubMed Web of Science ®Google Scholar
• Shrestha, R., O. Millington, J. Brewer, et al. 2014. Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways. Neuropharmacology. 76: 184–193
   PubMed Web of Science ®Google Scholar
• Price, A. L., N. J. Patterson, R. M. Plenge, et al. 2006. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38: 904–1099
   PubMed Web of Science ®Google Scholar
• Bielekova, B., M. Komori, Q. Xu, et al. 2012. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One. 7: e48370
   PubMed Web of Science ®Google Scholar
• Khademi, M., A. M. Dring, J. D. Gilthorpe, et al. 2013. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 8: e63172
   PubMed Web of Science ®Google Scholar
• Kivisäkk, P., B. C. Healy, V. Viglietta, et al. 2009. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 72: 1922–1930
   PubMed Web of Science ®Google Scholar
• Mellergård, J., M. Edström, M. Vrethem, et al. 2010. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 6: 208–217
   Google Scholar
• Hollifield, R. D., L. S. Harbige, D. Pham-Dinh, and M. K. Sharief. 2003. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity. 36: 133–141
   PubMed Web of Science ®Google Scholar